quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·24d
NEWSRelease
Telomir Pharmaceuticals Inc. logo

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

TELO· Telomir Pharmaceuticals Inc.
Health Care
Original source

Companies

  • TELO
    Telomir Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Feb 21UpdateRodman & Renshaw$15.00

Related

  • SEC2h
    Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
  • NEWS2h
    Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
  • SEC24d
    Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
  • SEC24d
    Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
  • SEC27d
    Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
  • SEC37d
    SEC Form 10-K filed by Telomir Pharmaceuticals Inc.
  • SEC63d
    SEC Form DEFM14A filed by Telomir Pharmaceuticals Inc.
  • SEC63d
    SEC Form DEFA14A filed by Telomir Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022